Literature DB >> 12070669

Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin.

Gesa Rascher1, Arne Fischmann, Stephan Kröger, Frank Duffner, Ernst-H Grote, Hartwig Wolburg.   

Abstract

The quality of the blood-brain barrier (BBB), represented mainly by endothelial tight junctions (TJ), is now believed to be dependent on the brain microenvironment and influenced by the basal lamina of the microvessels. In the highly vascularized glioblastoma multiforme (GBM), a dramatic increase in the permeability of blood vessels is observed but the nature of basal lamina involvement remains to be determined. Agrin, a heparan sulfate proteoglycan, is a component of the basal lamina of BBB microvessels, and growing evidence suggests that it may be important for the maintenance of the BBB. In the present study, we provide first evidence that agrin is absent from basal lamina of tumor vessels if the TJ molecules occludin, claudin-5 and claudin-1 were lacking in the endothelial cells. If agrin was expressed, occludin was always localized at the TJ, claudin-5 was frequently detected, whereas claudin-1 was absent from almost all vessels. Furthermore, despite a high variability of vascular phenotypes, the loss of agrin strongly correlated with the expression of tenascin, an extracellular matrix molecule which has been described previously to be absent in mature non-pathological brain tissue and to accumulate in the basal lamina of tumor vessels. These results support the view that in human GBM, BBB breakdown is reflected by the changes of the molecular compositions of both the endothelial TJ and the basal lamina.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070669     DOI: 10.1007/s00401-002-0524-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  54 in total

Review 1.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

Review 2.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 3.  In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro.

Authors:  R F Haseloff; I E Blasig; H C Bauer; H Bauer
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 4.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

5.  Multiple expression of matrix metalloproteinases in murine neurocysticercosis: Implications for leukocyte migration through multiple central nervous system barriers.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

Review 6.  Cellular elements of the blood-brain barrier.

Authors:  Jorge Correale; Andrés Villa
Journal:  Neurochem Res       Date:  2009-10-25       Impact factor: 3.996

7.  Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas.

Authors:  Peter Hau; Leoni A Kunz-Schughart; Petra Rümmele; Füsun Arslan; Anett Dörfelt; Horst Koch; Annette Lohmeier; Birgit Hirschmann; Adolf Müller; Ulrich Bogdahn; Anja-Katrin Bosserhoff
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

8.  β1-integrin/matrix interactions support blood-brain barrier integrity.

Authors:  Britta Engelhardt
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-20       Impact factor: 6.200

Review 9.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

Review 10.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.